Picture of Eli Lilly and logo

LLY — Eli Lilly and News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Eli Lilly’s $1.4 trln valuation is heavy with hope

BREAKINGVIEWS-Eli Lilly’s $1.4 trln valuation is heavy with hope

The author is a Reuters Breakingviews columnist. The opinions expressed are her own.

By Aimee Donnellan

- In December 2025, Eli Lilly LLY.N CEO David Ricks faced an unusual problem. His experimental drug was working too well. Trial participants taking the highest dose of his promising weight loss drug retatrutide lost an average of 28.7% of their body weight at 68 weeks. Nearly one in five on the top dose stopped treatment because of side effects, and some of them pulled out because they thought they were losing too much weight. Results like these, along with the success of Mounjaro and Zepbound, help explain Lilly's $1.4 trillion valuation. Yet despite the excitement, investors don't seem to be pricing in two glaring risks. Rival drugs will go generic and could drive prices down, and competitors could arrive with better-tolerated alternatives.

Lilly now dominates the GLP-1 market having overtaken Denmark’s Novo Nordisk NOVOb.CO which had arrived first. Last year, the US drug giant sold over $36 billion of Zepbound, its obesity drug, and Mounjaro, its diabetes treatment. Both contain the same active ingredient and produce significant weight loss. Analysts expect sales of these remedies to climb past $88 billion by 2030, according to Visible Alpha. Two things are behind the momentum. The first is the potency of its drugs. In clinical trials, patients lost more than 20.2% of their body weight on Lilly's Zepbound, versus around 18.7% on Novo's Wegovy, which is why more US physicians lean towards the first. The second is strategy. Ricks recognised early that these medicines behave more like consumer products than traditional pharmaceuticals. Lilly launched a website that sells directly to patients and offered vials that let them measure their own doses. That approach has made Ricks a star in pharma circles. Investors have rewarded him for repeatedly raising guidance.

Lilly's real promise, however, lies in its pipeline. Its experimental drug retatrutide is outperforming investor expectations in clinical trials and has produced more weight loss than any GLP-1 medication on the market. It isn't yet approved by the US Food and Drug Administration, and it's unclear how long its effects last. But in a world where investors are valuing weight loss over tolerability, the results are fueling confidence that Lilly can maintain its lead. The US company also has a number of related drugs in testing which may be easier to tolerate. That could be a game changer given around 50% of GLP-1 users stop taking the medication after six months of usage.

Yet even with new treatments, Ricks faces forces that could slow Lilly's momentum. The biggest comes from Novo Nordisk. Semaglutide, the active ingredient in the Danish drugmaker's blockbuster GLP-1 drugs Wegovy and Ozempic, sees its main US patent expire in 2031. Generic versions could drag down prices across the whole category through two ways. First, patients may switch to cut price injectables. Cost is regularly cited as one of the main reasons people stop taking GLP-1s. Second, US insurers and pharmacy benefit managers (PBMs), the middlemen who negotiate drug prices, could require patients try the generic before they will pay for Lilly's drugs which will dent demand. Pills add to the pressure. Oral versions of weight-loss drugs, such as Lilly's own orforglipron and Novo's Wegovy pill, are growing in popularity among patients who don't want shots. They typically cost about a third as much as injectables, which squeezes Lilly's pricing further.

Analysts are baking in a heavy dollop of hope into their forecasts. Eli Lilly’s sales of its current offering of GLP-1 drugs are projected to balloon in the coming years but then start to decline in 2031, following the loss of patent protection of Novo Nordisk's key drugs. But overall the US drug giant’s sales are set to increase by nearly 10% in the four years following, according to Visible Alpha forecasts. That bump stems from an increase in sales of neuroscience therapies, success in its oral weight loss drugs but mainly its pipeline. Berenberg analysts reckon that the net present value of Eli Lilly’s drugs and its existing pipeline is worth around $647 billion. That implies that the remaining $700 billion of the company's market value must come from investors assigning a greater probability of success in experimental therapies or stronger sales than Berenberg is forecasting.

The pipeline may warrant such enthusiasm. Investors are hotly anticipating the group’s “Innovation Day” scheduled for December 7 in Boston. Ricks could unveil plans for a monthly version of retatrutide, for instance. And he has a promising breast cancer candidate as well as other non-obesity related remedies that could do well. But the valuation leaves little room for error. Eli Lilly trades at more than thirteen times expected sales, while Novo Nordisk is valued at just four times, yet both face the same headwinds. The average pharma company is worth less than three times, per LSEG data.

The question for Ricks is, can his pipeline deliver enough sales to offset a decline in GLP-1 revenue from increased competition and falling prices? Investors are not pricing in any risk of failure. That seems like a hefty bet in an industry where 90% of drugs never make it to market.

Follow Aimee Donnellan on LinkedIn.


(Editing by Robert Cyran; Production by Pranav Kiran)

((For previous columns by the author, Reuters customers can click on DONNELLAN/Aimee.Donnellan@thomsonreuters.com))

Recent news on Eli Lilly and

See all news